The FDA granted accelerated approval to mosunetuzumab (Lunsumio; Genentech), a CD20/CD3 bispecific T-cell engager administered as a subcutaneous injection for patients with relapsed or refractory ...

You may want to lose body fat but might not know exactly where fat is stored in your body. That’s when knowing the difference between subcutaneous fat and visceral fat can be handy. The main ...

Dose intensification of subcutaneous vedolizumab is beneficial for patients with IBD, particularly those with UC. Subcutaneous vedolizumab dose escalation is associated with clinical improvement in ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially ...

The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...